City of Hope

www.cityofhope.org

 

ASH 2022 Conference Coverage
F

ASH 2022 Understanding and Monitoring Resistance to Anti-CD38 and -BCMA Therapies

By ASH 2022 Conference Coverage FEATURING Flavia Pichiorri
By ASH 2022 Conference Coverage FEATURING Flavia Pichiorri
203 views
January 4, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

19:25
Pfizer Hematology

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip

Featured Video

18:30
Pfizer Hematology

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Feat. A. Whiteley
Myeloma
11:43

Practical Perspectives on Recent CAR-T FDA Approvals in Myeloma

City of Hope

M. Janakiram

288 views
20:46

ASH 2022 Understanding and Monitoring Resistance to Anti-CD38 and -B…

ASH 2022 Conference Coverage

F. Pichiorri

203 views
07:29

ASCO 2021 Updated Phase 1 Results of Teclistamab, a B-Cell Maturatio…

City of Hope

A. Krishnan

124 views
18:44

The Promise of Immunotherapy and Newer Agents in Multiple Myeloma

City of Hope

A. Krishnan

495 views
17:58

Should Everyone Receive Monoclonal Antibodies at First Myeloma Relap…

City of Hope

J. Mikhael

490 views